ClinicalTrials.gg
CompletedNCT03845582SAGAUpdated Nov 3, 2025Results posted

Phase 2/3 Study of ALK-001 in Geographic Atrophy

A Phase 2/3 interventional study of ALK-001 oral capsule and Placebo oral capsule in Geographic Atrophy, Age Related Macular Degeneration and AMD, sponsored by Alkeus Pharmaceuticals, Inc.. Completed at 24 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by Alkeus Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
40th of 107
200 · median 98
Started
2019
with 8 others
Phase 2/3
5 of 131
1 open now
Registered
59th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 40th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2019, is one of 5 in phase 2/3, and was the 59th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).

Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

Read the detailed description

There is no oral treatment available for Geographic Atrophy secondary to AMD. AMD is characterized by an age-related degeneration of the retina.

The root cause for this degeneration or why some people develop AMD while others do not, is unknown. Over 20 years ago, it was hypothesized that the dimerization of vitamin A may be a significant contributor to the etiology of AMD. The eye indeed uses vitamin A as a cofactor to sense light, and a striking chemical signature of the aging and degenerating retina is the accumulation of vitamin A dimers in the retinal pigment epithelium (RPE) and the underlying Bruch's membrane. In rodent models, high levels of vitamin A dimers correlate with poor retinal health, and a variety of mechanisms have been proposed by which vitamin A dimers may induce retinal toxicity. It has been argued that these mechanisms participate in the development and progression of AMD.

ALK-001, the study drug, is a modified form of vitamin A. When taken once a day as a capsule, it replaces natural vitamin A in the body with one that forms vitamin A dimers more slowly. This study will measure the extent to which treatment with ALK-001 slows the progression of Geographic Atrophy.

03

Conditions studied

  • Geographic Atrophy
  • Age Related Macular Degeneration
  • AMD
  • Atrophy, Geographic
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

- At least one eye with geographic atrophy secondary to dry age-related macular degeneration (AMD)

Major Exclusion Criteria:

- Medical condition, which may interfere with the progression of GA, prevent performance of study procedures, compliance with protocol, or continuous participation in the study

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    ALK-001

    Capsule

    Drug: ALK-001 oral capsule

  • Placebo comparator
    Placebo

    Capsule

    Drug: Placebo oral capsule

Interventions

  • Daily administration for 24 months

    Also known as: C20-D3-Retinyl Acetate, C20 Deuterated vitamin A

  • DrugPlacebo oral capsule

    Daily administration for 24 months

06

What researchers measure

Primary outcomes

  1. Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)

    Time frame: Baseline to 24 months

Secondary outcomes

  1. Number of Participants With Adverse Events

    Time frame: Baseline to 24 months

  2. Changes in Visual Acuity

    Changes in LLVA and BCVA

    Time frame: Baseline to 24 months

07

Results

Posted Oct 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneALK-001Placebo
Started13563
Completed9443
Not completed4120

Outcome measures

PrimaryGrowth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)
Time frame:
Baseline to 24 months
Reported as:
Least squares mean · mm2/year
Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)
mm2/yearALK-001Placebo
Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)1.62 ± 0.0811.87 ± 0.116
SecondaryNumber of Participants With Adverse Events
Time frame:
Baseline to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsALK-001Placebo
Number of Participants With Adverse Events9752
SecondaryChanges in Visual Acuity

Changes in LLVA and BCVA

Time frame:
Baseline to 24 months
Reported as:
Least squares mean · letters
Changes in Visual Acuity
lettersALK-001Placebo
LLVA-3.896 ± 1.316-8.298 ± 1.835
BCVA-6.862 ± 1.251-10.161 ± 1.771

Adverse events

Collected over Two years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALK-0015/135 (3.7%)26/135 (19.3%)59/135 (43.7%)
Placebo1/63 (1.6%)14/63 (22.2%)34/63 (54%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventALK-001Placebo
Corona virus infectionInfections and infestations0/1353/63
Cerebrovascular accidentNervous system disorders5/1351/63
Hip fractureInjury, poisoning and procedural complications0/1352/63
PneumoniaInfections and infestations3/1350/63
DeathGeneral disorders3/1351/63
SyncopeNervous system disorders0/1351/63
Supraventricular extrasystolesCardiac disorders0/1351/63
InfectionInfections and infestations0/1351/63
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1351/63
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1351/63
Most frequent other events
Most frequent other events
EventALK-001Placebo
Blood triglycerides increasedInvestigations15/1355/63
Corona virus infectionInfections and infestations7/1356/63
FallInjury, poisoning and procedural complications9/1356/63
Blood alkaline phosphatase increasedInvestigations10/1355/63
Urinary tract infectionInfections and infestations5/1355/63
Glomerular filtration rate decreasedInvestigations6/1354/63
ArthralgiaMusculoskeletal and connective tissue disorders7/1353/63

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ALK-001PlaceboTotal
<=18 years000
Between 18 and 65 years538
>=65 years13060190
Sex: Female, Male
Sex: Female, Male(Participants)ALK-001PlaceboTotal
Female9145136
Male441862
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ALK-001PlaceboTotal
Hispanic or Latino246
Not Hispanic or Latino13359192
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)ALK-001PlaceboTotal
United States13563198
08

Study locations

24 sites
  • Alkeus Site
    Phoenix, Arizona 85053, United States
  • Alkeus Site
    Beverly Hills, California 90211, United States
  • Alkeus Site
    Lakewood, Colorado 80228, United States
  • Alkeus Site
    Clearwater, Florida 33761, United States
  • Alkeus Site
    Fort Myers, Florida 33912, United States
  • Alkeus Site
    Gainesville, Florida 32601, United States
  • Alkeus Site
    Tampa, Florida 33609, United States
  • Alkeus Site
    Winter Haven, Florida 33880, United States
  • Alkeus Site
    Bloomington, Illinois 61704, United States
  • Alkeus Site
    Lexington, Kentucky 40509, United States
  • Alkeus Site
    Chevy Chase, Maryland 20815, United States
  • Alkeus Site
    Worcester, Massachusetts 01605, United States
  • Alkeus Site
    Grand Rapids, Michigan 49546, United States
  • Alkeus Site
    Edina, Minnesota 55435, United States
  • Alkeus Site
    Northfield, New Jersey 08225, United States
  • Alkeus Site
    Great Neck, New York 11021, United States
  • Alkeus Site
    Hauppauge, New York 11788, United States
  • Alkeus Site
    Cleveland, Ohio 44122, United States
  • Alkeus Site
    Ashland, Oregon 97520, United States
  • Alkeus Site
    Houston, Texas 77025, United States
  • Alkeus Site-1
    San Antonio, Texas 78240, United States
  • Alkeus Site-2
    San Antonio, Texas 78240, United States
  • Alkeus Site
    Fairfax, Virginia 22031, United States
  • Alkeus Site
    Silverdale, Washington 98383, United States
09

References and documents

Publications

  • Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-7965. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12. PubMed 21075840 ↗
  • Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-D(3)-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013. PubMed 23914132 ↗
  • Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47. PubMed 26427432 ↗
  • Boyer DS, Saad L, Washington I, Melamud A, Graham KB, O'Malley AE, DeBartolomeo GM, Jiang H, Harris LD, Kay CN, Ferrone PJ, Khan S; SAGA Study Team. Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy Randomized Clinical Trial. Ophthalmol Retina. 2026 Jun 3:S2468-6530(26)00268-X. doi: 10.1016/j.oret.2026.05.018. Online ahead of print. PubMed 42242606 ↗
  • Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5. PubMed 37702300 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jul 2023, 50 months.

Results were first posted in Oct 2025, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2019
First posted
Feb 19, 2019
StartActual
May 7, 2019
Primary completionActual
Jul 25, 2023
CompletionActual
Jun 30, 2024
Results first posted
Oct 16, 2025
Last update
Nov 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03845582
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
May 7, 2019
Primary completion
Jul 25, 2023
Completion
Jun 30, 2024
Results posted
Oct 16, 2025
Last update
Nov 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gildeuretinol acetate

Start the discussion